TransCode Therapeutics, Inc. - Common Stock (RNAZ)
7.5600
-0.4900 (-6.09%)
Transcode Therapeutics Inc is a biotechnology company focused on developing innovative RNA-based therapeutics aimed at treating cancer and other serious diseases
The company specializes in harnessing the potential of RNA to create targeted therapies that can address the underlying mechanisms of diseases, particularly in oncology. By leveraging its proprietary technology platforms, Transcode aims to enhance the precision of cancer treatments and improve patient outcomes, while also exploring applications in other therapeutic areas. The company's commitment to advancing RNA therapeutics positions it at the forefront of cutting-edge research in the life sciences field.
Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's approval of a 1-for-33 reverse stock split.
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
TransCode Therapeutics Inc. (NASDAQRNAZ) shares are moving higher Friday after the company announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with its lead candidate, TTX-MC138 on Tuesday.
